CDC42 and prostate carcinoma: Our findings fit quite well with the studies by Edlund et al. [53], here pretreatment with the PI3K inhibitor LY294002 did not abolish the Smad7-induced activation of Cdc42 in human prostate cancer cell line (PC-3U).